Affiliation:
1. Allergy Center, National Center for Child Health and Development Tokyo Japan
2. Department of Dermatology Nippon Medical School Tokyo Japan
3. Specialty Care Medical, Sanofi K.K. Tokyo Japan
4. Market Access, Sanofi K.K. Tokyo Japan
5. Sanofi Cambridge Massachusetts USA
6. Sanofi Chilly‐Mazarin France
Abstract
AbstractBackgroundAtopic dermatitis (AD) is a chronic skin condition that is associated with significant patient burden and decreased health‐related quality of life (HRQoL). We report results of the real‐world Epidemiology of Children with Atopic Dermatitis Reporting on their Experience study in Japanese pediatric patients, focusing on the impact of AD severity on disease burden.MethodsChildren and adolescents aged 6 months to 17 years (or their caregivers/parents) completed an online survey between September 26, 2018, and March 5, 2019. Patients with diagnosed AD (i.e., met International Study of Asthma and Allergies in Childhood criteria and had a self‐reported AD diagnosis) were evaluated for disease severity using the Patient‐Oriented Eczema Measure (POEM). Impact of AD severity on AD symptoms (itching, pain, and sleep disturbance), disease flares, atopic comorbidities, healthcare resource utilization, school days missed, and HRQoL were assessed.ResultsOf 5702 Japanese pediatric patients, 547 had diagnosed AD and were included in this analysis. Based on POEM scores, AD severity was clear/mild in 346 patients (63.3%), moderate in 177 (32.5%), and severe in 24 (4.4%). Across all age groups (i.e., less than 6, 6–11, and 12–17 years), increased AD severity was associated with increased AD symptom severity, number of flares, atopic comorbidities, healthcare resource utilization, and school absences, as well as worsened HRQoL.ConclusionsThis population‐based study of Japanese children and adolescents showed that greater AD severity had a high impact on disease burden.
Subject
Dermatology,Pediatrics, Perinatology and Child Health